

Florian Schuetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3606690/publications.pdf>

Version: 2024-02-01

56
papers

1,574
citations

304368

22
h-index

301761

39
g-index

57
all docs

57
docs citations

57
times ranked

2811
citing authors

#	ARTICLE	IF	CITATIONS
1	Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 353-362.	2.0	196
2	Gene Expression Signature Predicting Pathologic Complete Response With Gemcitabine, Epirubicin, and Docetaxel in Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1839-1845.	0.8	146
3	B cell-regulated immune responses in tumor models and cancer patients. <i>Oncolmunology</i> , 2013, 2, e25443.	2.1	126
4	Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. <i>Anti-Cancer Drugs</i> , 2007, 18, 477-485.	0.7	75
5	Interobserver reliability of automated breast volume scanner (ABVS) interpretation and agreement of ABVS findings with hand held breast ultrasound (HHUS), mammography and pathology results. <i>European Journal of Radiology</i> , 2013, 82, e332-e336.	1.2	66
6	Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis. <i>Cancer Research</i> , 2009, 69, 8420-8428.	0.4	55
7	Do Reexcisions Impair Aesthetic Outcome in Breast Conservation Surgery? Exploratory Analysis of a Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 541-547.	0.7	51
8	Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy. <i>Breast</i> , 2013, 22, 537-542.	0.9	48
9	Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 887-900.	2.0	46
10	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	1.1	45
11	Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1053-1060.	2.0	42
12	Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. <i>Oncolmunology</i> , 2016, 5, e1057387.	2.1	38
13	Objective assessment of aesthetic outcome after breast conserving therapy: Subjective third party panel rating and objective BCCT.core software evaluation. <i>Breast</i> , 2012, 21, 61-65.	0.9	36
14	Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 342.e1-342.e9.	0.7	35
15	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , 2016, 11, 102-107.	0.8	35
16	Predictors of early poor aesthetic outcome after breast-conserving surgery in patients with breast cancer: Initial results of a prospective cohort study at a single institution. <i>Journal of Surgical Oncology</i> , 2014, 110, 801-806.	0.8	34
17	Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. <i>Anticancer Research</i> , 2014, 34, 6609-15.	0.5	32
18	Side Effects of Bone-Targeted Therapies in Advanced Breast Cancer. <i>Breast Care</i> , 2014, 9, 332-336.	0.8	30

#	ARTICLE	IF	CITATIONS
19	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock Breast Cancer: Reliability Study. Journal of Medical Internet Research, 2019, 21, e10004.	2.1	29
20	Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. Anti-Cancer Drugs, 2014, 25, 219-224.	0.7	27
21	Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.. Journal of Clinical Oncology, 2017, 35, 1061-1061.	0.8	25
22	Prognostic Value of Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term Follow-up Study. Annals of Surgical Oncology, 2013, 20, 1865-1871.	0.7	24
23	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 2021, 154, 128-137.	1.3	24
24	Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anti-Cancer Drugs, 2007, 18, 963-968.	0.7	24
25	Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications. Cancer and Metastasis Reviews, 2013, 32, 163-178.	2.7	22
26	HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology, 2013, 2, e24962.	2.1	22
27	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686.	1.5	20
28	Breast Cancer Mastectomy Trends Between 2006 and 2010: Association with Magnetic Resonance Imaging, Immediate Breast Reconstruction, and Hospital Volume. Annals of Surgical Oncology, 2013, 20, 3839-3846.	0.7	19
29	Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. Cancer Immunology, Immunotherapy, 2017, 66, 593-603.	2.0	19
30	Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications. Supportive Care in Cancer, 2017, 25, 549-558.	1.0	19
31	Adoptive immunotherapy of metastatic breast cancer: present and future. Cancer and Metastasis Reviews, 2014, 33, 309-320.	2.7	18
32	Therapeutic effects of metformin in breast cancer: involvement of the immune system?. Cancer Immunology, Immunotherapy, 2011, 60, 1221-1225.	2.0	17
33	Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget, 2017, 8, 51416-51428.	0.8	16
34	Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. Annals of Surgical Oncology, 2016, 23, 757-766.	0.7	15
35	Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. Anti-Cancer Drugs, 2005, 16, 1023-1028.	0.7	11
36	PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncology Letters, 2017, 13, 2847-2851.	0.8	11

#	ARTICLE	IF	CITATIONS
37	Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. <i>Cancers</i> , 2019, 11, 342.	1.7	8
38	Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 479-486.	2.0	7
39	Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4173-4180.	1.0	7
40	Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e16128.	2.1	6
41	Bevacizumab in the Treatment of Metastatic Breast Cancer. <i>Breast Care</i> , 2007, 2, 82-88.	0.8	5
42	Intraoperative bone marrow puncture in breast cancer patients: Prospective assessment of adverse side-effects. <i>Breast</i> , 2011, 20, 62-65.	0.9	5
43	Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 123-129.	0.8	5
44	Exam preparatory course for the 2nd part of the German medical examination in obstetrics and gynecology – a potential tool for the recruitment of new residents during the occupational decision process before the practical year?. <i>BMC Medical Education</i> , 2019, 19, 24.	1.0	5
45	Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 401-411.	2.0	4
46	Adjuvant Systemic Therapy of Breast Cancer. <i>Breast Care</i> , 2011, 6, 179-183.	0.8	4
47	Exam preparation course in obstetrics and gynecology for the German Medical State Examination: proof of concept and implications for the recruitment of future residents. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1235-1241.	0.8	4
48	Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 971-978.	0.8	4
49	Influence of Paclitaxel and Heparin on Vitality, Proliferation and Cytokine Production of Endometrial Cancer Cells. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1104-1110.	0.8	4
50	Parity improves anti-tumor immunity in breast cancer patients. <i>Oncotarget</i> , 2017, 8, 104981-104991.	0.8	4
51	Breast cancer presentation and therapy in migrant versus native German patients: contrasting and convergent data of a retrospective monocentric study. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 145-152.	0.8	3
52	Do Contralateral Prophylactic Mastectomies Help Patients?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4191-4191.	0.8	1
53	Evaluation of the anti-Thomsen-Friedenreich antibodies Nemo-TF1 and Nemo-TF2 as prognostic markers in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 643-652.	1.1	0
54	Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1096-1096.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. Journal of Clinical Oncology, 2012, 30, 1090-1090.	0.8	0
56	Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO.. Journal of Clinical Oncology, 2017, 35, e12547-e12547.	0.8	0